|
summary: This review looks at cladiribine, a new oral agent
that has been tried in relapsing-remitting and progressive MS. It has been shown to reduce enhancing lesions but the clinical significance of this is unclear and bone marrow suppression was a side effect. The authors conclude that more studies are needed.
authors: Brousil JA, Roberts RJ, Schlein AL.
source: Ann Pharmacother. 2006 Oct;40(10):1814-21. Epub 2006 Sep 19.
weblink: click here
category: Clinical Trials and Therapeutics
related research news: click here
glossary:
Bone marrow
Immunoglobulin
Immunosuppressio
Lesion
Multiple sclerosis
Plaque
Relapsing/remitting MS
Sclerosis
Sign
|
